Call for software guidance
This article was originally published in Clinica
The FDA's CDRH continues to solicit industry advice about a possible new software policy. Under consideration is a risk-based approach that would mainly regulate high-risk products and ignore low-risk software such as laboratory information management systems. To speed the rulemaking process, the agency might propose a negotiated rulemaking involving arbitration with industry.